<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03375047</url>
  </required_header>
  <id_info>
    <org_study_id>MRT5005-101</org_study_id>
    <nct_id>NCT03375047</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety &amp; Tolerability of MRT5005 Administered by Nebulization in Adults With Cystic Fibrosis</brief_title>
  <acronym>RESTORE-CF</acronym>
  <official_title>A Phase 1/2, Randomized, Double-Blinded, Placebo-Controlled, Combined Single and Multiple Ascending Dose Study Evaluating the Safety, Tolerability, and Biological Activity of MRT5005 Administered by Nebulization to Adult Subjects With Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Translate Bio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Translate Bio, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 1/2, first-in-human study will evaluate the safety and tolerability of single and
      multiple escalating doses of MRT5005 administered by nebulization to the respiratory tract of
      adult subjects with CF. This study will also assess the delivery of the drug to bronchial
      epithelial cells following multiple doses of MRT5005, and will characterize its biological
      activity by measuring changes in CFTR protein levels and CFTR chloride channel activity
      post-treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 10, 2018</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Types, frequency and severity of treatment-emergent Adverse Events</measure>
    <time_frame>12 months after last dose</time_frame>
    <description>Safety and tolerability of nebulized MRT5005 will be assessed through the types , frequency and severity of treatment-emergent Adverse Events experienced by participants on the trial</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Delivery of mRNA</measure>
    <time_frame>24 hours after 5th dose</time_frame>
    <description>Assessment of delivery of the mRNA to the bronchial epithelial cells by qPCR</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose of MRT5005</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mid Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mid dose of MRT5005</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose of MRT5005</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal Saline 0.9% USP</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MRT5005</intervention_name>
    <description>Nebulization of MRT5005</description>
    <arm_group_label>Low Dose</arm_group_label>
    <arm_group_label>Mid Dose</arm_group_label>
    <arm_group_label>High Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Normal Saline for Inhalation</description>
    <arm_group_label>Placebo Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of CF as defined by all of the following:

               -  A sweat chloride value of ≥60 mmol/L by quantitative pilocarpine iontophoresis
                  (documented in the subject's medical record).

               -  Two CF disease-causing CFTR mutations in Class I or II (genotype confirmed at the
                  screening visit).

               -  Chronic sinopulmonary disease and/or gastrointestinal/nutritional abnormalities
                  consistent with CF disease.

          -  Clinically stable CF disease, as judged by the investigator.

          -  FEV1 ≥50% and ≤90% of the predicted normal for age, gender, and height at screening.

          -  Resting oxygen saturation ≥92% on room air (pulse oximetry).

        Exclusion Criteria:

          -  An acute upper or lower respiratory infection, pulmonary exacerbation, clinically
             significant episode of hemoptysis or change in chronic respiratory medications
             (including antibiotics) for CF lung disease within 28 days prior to dosing with
             investigational product on Day 1.

          -  Receiving treatment with ivacaftor monotherapy (KALYDECO).

          -  Subjects with a Class III, IV, or V CFTR gene mutation in at least 1 allele.

          -  Infection with highly virulent bacteria associated with accelerated decline in
             pulmonary function and/or decreased survival (e.g., Burkholderia cenocepacia,
             Burkholderia dolosa, Mycobacterium abscessus).

        Treatment with ORKAMBI is not an exclusion for this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Caroline O'Hara</last_name>
    <phone>8572092450</phone>
    <email>cohara@translate.bio</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>New Orleans Center for Clinical Research</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Alton EWFW, Armstrong DK, Ashby D, Bayfield KJ, Bilton D, Bloomfield EV, Boyd AC, Brand J, Buchan R, Calcedo R, Carvelli P, Chan M, Cheng SH, Collie DDS, Cunningham S, Davidson HE, Davies G, Davies JC, Davies LA, Dewar MH, Doherty A, Donovan J, Dwyer NS, Elgmati HI, Featherstone RF, Gavino J, Gea-Sorli S, Geddes DM, Gibson JSR, Gill DR, Greening AP, Griesenbach U, Hansell DM, Harman K, Higgins TE, Hodges SL, Hyde SC, Hyndman L, Innes JA, Jacob J, Jones N, Keogh BF, Limberis MP, Lloyd-Evans P, Maclean AW, Manvell MC, McCormick D, McGovern M, McLachlan G, Meng C, Montero MA, Milligan H, Moyce LJ, Murray GD, Nicholson AG, Osadolor T, Parra-Leiton J, Porteous DJ, Pringle IA, Punch EK, Pytel KM, Quittner AL, Rivellini G, Saunders CJ, Scheule RK, Sheard S, Simmonds NJ, Smith K, Smith SN, Soussi N, Soussi S, Spearing EJ, Stevenson BJ, Sumner-Jones SG, Turkkila M, Ureta RP, Waller MD, Wasowicz MY, Wilson JM, Wolstenholme-Hogg P; UK Cystic Fibrosis Gene Therapy Consortium. Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med. 2015 Sep;3(9):684-691. doi: 10.1016/S2213-2600(15)00245-3. Epub 2015 Jul 3. Erratum in: Lancet Respir Med. 2015 Sep;3(9):e33.</citation>
    <PMID>26149841</PMID>
  </reference>
  <reference>
    <citation>Calcedo R, Griesenbach U, Dorgan DJ, Soussi S, Boyd AC, Davies JC, Higgins TE, Hyde SC, Gill DR, Innes JA, Porteous DJ, Alton EW, Wilson JM, Limberis MP. Self-reactive CFTR T cells in humans: implications for gene therapy. Hum Gene Ther Clin Dev. 2013 Sep;24(3):108-15. doi: 10.1089/humc.2012.249. Epub 2013 Jul 19.</citation>
    <PMID>23790242</PMID>
  </reference>
  <reference>
    <citation>Besançon F, Przewlocki G, Baró I, Hongre AS, Escande D, Edelman A. Interferon-gamma downregulates CFTR gene expression in epithelial cells. Am J Physiol. 1994 Nov;267(5 Pt 1):C1398-404.</citation>
    <PMID>7526699</PMID>
  </reference>
  <reference>
    <citation>Danel C, Erzurum SC, McElvaney NG, Crystal RG. Quantitative assessment of the epithelial and inflammatory cell populations in large airways of normals and individuals with cystic fibrosis. Am J Respir Crit Care Med. 1996 Jan;153(1):362-8.</citation>
    <PMID>8542144</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2017</study_first_submitted>
  <study_first_submitted_qc>December 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 15, 2017</study_first_posted>
  <last_update_submitted>May 17, 2018</last_update_submitted>
  <last_update_submitted_qc>May 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cystic Fibrosis</keyword>
  <keyword>CF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

